After the emergence of the use of TKIs targeting KIT/PDGFRA [37], the main systemic therapy development in GIST has targeted ABP and AL mutations, which are found to be present after treatment with imatinib. This evidence concerns the gene KIT and gastrointestinal stromal tumor.